CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
June 10, 2021 11:19 ET
|
CVRx, Inc.
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the...
Caregiver Action Network Announces New Resource for Families of Loved Ones with Heart Failure
June 08, 2021 13:46 ET
|
Caregiver Action Network
Washington, DC, June 08, 2021 (GLOBE NEWSWIRE) -- Hearing that a loved one has been diagnosed with heart failure brings fear, stress, and a whole lot of questions. Caregiver Action Network has...
Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress
April 22, 2021 16:32 ET
|
Cardiometabolic Health Congress
Boca Raton, FL, April 22, 2021 (GLOBE NEWSWIRE) -- Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress Top Experts Convene to Discuss the Syndemic of COVID-19 &...
Fierce Medtech Names CVRx as One of its “Fierce 15” Companies
March 15, 2021 10:00 ET
|
CVRx, Inc.
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announces it has been selected...
BERLIN HEALS Announces results of first-in-human study for its Implantable C-MIC device for the Treatment of Heart Failure with Electrical Microcurrent and the Launch of a pivotal CE Mark Study
March 04, 2021 11:00 ET
|
Berlin Heals Holding AG
BERLIN and ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- BERLIN HEALS, a company dedicated to developing and offering novel and life-saving treatments for patients suffering from heart...
CHF Solutions’ Physician-Led Webinar Highlights Real-World Evidence Supporting Effectiveness of Ultrafiltration in Heart Failure Patients
January 28, 2021 08:00 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...
CHF Solutions Offers Educational Event on Effective Fluid Management Strategies in Heart Failure Patients
January 21, 2021 08:00 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...
CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing
January 05, 2021 10:55 ET
|
CVRx, Inc.
MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...
BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Heart Failure Study as Designed
December 17, 2020 08:30 ET
|
BioCardia, Inc.
SAN CARLOS, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that...
CHF Solutions Announces Meta-Analysis Demonstrates Ultrafiltration is Better than Diuretic Therapy for the Management of Volume Overload in ADHF
December 15, 2020 08:00 ET
|
CHF Solutions, Inc.
EDEN PRAIRIE, Minn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...